|Type of cell therapy
|Convalescent plasma therapy
||Plasma from donors who have recovered from COVID-19 may contain antibodies to SARS-CoV-2.
||Suppress the virus and modify the inflammatory response.
|Immunotherapy, including the transfer of T cells from convalescent donors and engineered NK cells
||Goal is to develop cells that will help the host modify various inflammatory/immune responses.
||Reduce overall disease severity.
|Mesenchymal stem cells/medicinal signaling cells and their derivatives
||Potential immunomodulatory effect via secretion of cytokines, chemokines, growth factors and extracellular vesicles, or direct interaction with immune cells.
||Limit inflammation and limit lung fibrosis.
|Lung stem cells (through clonal expansion or iPSC differentiation)
||Improve endogenous repair of damaged tissue in lungs of recovered patients suffering from alveolar damage.
|Exosomes, derived from various sources e.g. T cells, amniotic fluid
||Five COVID-19 exosome clinical trials have been registered.
||Mechanisms unknown, despite the promising therapeutic potential of exosomes.